This order provides for the testing of 26 compounds against the AKT1 and LATS1 compounds in a NanoBRET target Engagement Intracellular Kinase Assay. This testing will inform on kinase inhibitory activity in our compound series, and will facilitate further optimization and development of these AKT1 / LATS1 compounds as well as potential treatments.